AiCuris is a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria. AiCuris‘ mission is the development of innovative drugs against severe and life-threatening infectious diseases with high medical need. AiCuris aims to be THE successful innovator for antiviral and antibacterial therapy.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.

Guangzhou Yaoben Junan Pharmaceutical Technology Co., Ltd., established on 2016-07-04, Business scope includes drug research and development;Human Science Research,to develop;Health Sciences Program Research,to develop;Food Science and Technology Research Services;Human Science Research Achievement Transfer Service;Health Sciences Program Research Transfer;Technology Promotion of Research Results of Health Science Projects;Manufacturing of organic chemical raw materials(Monitor Chemicals,Excluding hazardous chemicals);Manufacturing of chemical raw materials;Production of Chinese herbal extracts(The specific business items are subject to the drug production license);Health food manufacturing;soy sauce,Manufacture of vinegar and similar products;Manufacturing of chemical preparations;Health food wholesale(Specific business items are<food business license>prevail);Health Food Retail(Specific business items are<food business license>prevail);Wholesale Prepackaged Food;Prepackaged Food Retail

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

CnPharm Co., Ltd. is a South Korean private company that engages in research and experimental development.

Lab Pathways, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area.\nIn 2010, CeeTox purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox's existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings.\nThe scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process.

Shanghai Yunshun Biotechnology Co., Ltd., established on 2014-07-07, Business scope includes general items:Biotechnology,medical technology,Technical services in the field of food monitoring technology,technology development,technology transfer,technical consulting,teaching aids,laboratory equipment,Experimental consumables,Instrumentation,Class I medical device,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),cosmetic,Edible produce(In addition to pigs,Cattle,Livestock products such as sheep)promotion of,Market information consultation and investigation(Do not engage in social investigation,social research,poll,opinion poll),Business Consulting(Consulting projects except brokerage),investment management,Sales of Class II Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Nihon Medi-Physics Co., Ltd. is a Japanese joint venture company located in Koto-ku focused on pharmaceutical preparations. The firm was founded in 1973. Nobuhiko Tamura is the current CEO of the company.\nThe company says this about itself: Nihon Medi-Physics is engaging in ensuring stable supply and research and development of the products as a leading manufacturer of radiopharmaceuticals in Japan. Based on the technological proficiency and trust built over the years, the company is also working on research and development of \"Theranostics (a combination of therapy and diagnosis),\" which is a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. The company will continue contributing to society by creating values as a life science company.

Tianjin Exosome Technology Co., Ltd., established on 2021-07-02, Business scope includes medical research and experimental development;Cell technology research and application;Engineering and Technology Research and Experimental Development;Natural science research and experimental development;New material technology research and development;New material technology promotion service;pharmaceutical production;Human stem cell technology development and application;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology intermediary service;Import and export;Drug import and export;Technology Import and Export;Production of Class I Medical Devices;Production of Class II Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Jiangxi Huanong Hengqing Agriculture and Animal Husbandry Co., Ltd., established on 2011-03-09, Business scope includes licensed projects:feed production,Feed additive production,aquaculture,poultry farming,animal husbandry,poultry slaughter,livestock slaughter,Livestock raising,road freight transport(Does not contain dangerous goods)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Animal Husbandry and Fishery Feed Sales,Feed Raw Material Sales,Bio-feed R&D,Feed Additive Sales,Livestock manure treatment,livestock sales,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Research and development of technology for the harmless utilization of agricultural and forestry waste resources,Engage in investment activities with own funds(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)